News & Comment

An industry academic liaison officer and a university technology-transfer professional in the UK canvass their peers to provide some pointers for how to streamline the technology-transfer process between companies and academia.

Striking partnerships is a key ingredient to building a biotech company. In this article, we discuss seven common mistakes that you should avoid during business development.

Starting and sustaining a business in the life sciences is not for the faint of heart. And in an increasingly complex business environment, biotech entrepreneurs should look for complementary partners and new business opportunities to effectively build their companies.

The public markets aren't what they used to be and venture capitalists are seeking investments with shorter timelines. But the good news is several new sources of financing are becoming available.

Working with patient advocacy groups poses many challenges to entrepreneurs, but the benefits can be substantial. Here, we examine the relationship between biotech PTC Therapeutics and Parent Project Muscular Dystrophy to highlight some key factors for success in such partnerships.

There's a lot to consider before out-licensing patent rights. Here, a law student and a seasoned patent attorney outline what every bioentrepreneur should know before tackling the task.

Many cities and countries still view the foundation of a biotech sector as desirable for a high-tech, intellectually driven economy. But a discussion by seasoned biotech management and investors suggests that attaining an environment with the right mix of money, management and innovation remains a difficult and long-term challenge.

A veteran of the tech transfer business offers guidance on how to manage interuniversity research—and how to avoid the wrangling over IP that often accompanies invention.

Pharma has pipelines to fill and cash to spend. But just what types of partners and products is it looking for?

Many biotech products experience setbacks and disappointments along the path to commercial success. Here, three industry insiders provide some suggestions for the best practice when a product is returned or discontinued by a licensee.

A serial entrepreneur provides his insights into the pitfalls you may face when seeking financing for your company and some key strategies to avoid them.

Two of KPMG in the UK's tax consultants summarize basic tax principles to bear in mind when starting a life science venture.

Charitable foundations are increasingly looking to help promising drugs reach the market. Often the advice and networking opportunities they provide are as valuable as the funding.

For most biotech companies, the US market represents their best avenue to financial success. For non-US companies, that might mean opening a subsidiary, and that's a move that requires careful planning.

Europe has a substantial big pharma presence and a continuing tradition of scientific excellence, but several factors still hinder the development of a vibrant biotech sector.

Conflicts of interest in research can affect a company's ability to move a product through the approval process or attract investment. Avoid the pitfalls by taking pro-active steps to manage these risks.

The path may not always be clear, but government money to support biotech startups is there for the asking. You just need to know where to look.

The first few decisions bioentrepreneurs make when forming a company can come back to bite them later, but some careful planning can smooth the way for later success.

There's another kind of venture capitalist lurking in the corridors of capital.

As well as overcoming legal, cultural and linguistic barriers, European biotech companies must focus on building investor visibility, pharma collaborations and consolidation to boost their chances of successful exits.